NEW YORK--(BUSINESS WIRE)-- Synergy Pharmaceuticals, Inc. (NASDAQ: SGYPD, SGYPU), a developer of new drugs to treat gastrointestinal disorders and diseases, announced the closing of its underwritten ...
The common stock and warrants will not be separately transferable until the earlier of (i) the exercise in full of the underwriters' overallotment option or (ii) 45 days from the date of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback